acrolein, e-cigarettes, and pulmonary and vascular damage.
Individual Clinical
Safety
Adverse Effects
Kuntic (2020)
Biomarkers of Exposure Specific to E-vapor Products Based on Stable-Isotope Labeled Ingredients.
Individual Clinical
Biomarkers
Biomarkers Of Exposure
Landmesser (2019)
Safety Report on the Ruyan® e-cigarette Cartridge and Inhaled aerosol
Individual Clinical
Safety
Laugesen (2008)
Comparison of toxicant levels in mainstream aerosols generated by Ruyan® electronic nicotine delivery systems (ENDS) and conventional cigarette products
Individual Clinical
Respiratory Toxicity
Lauterbach (2012)
Molecular and neuronal mechanisms underlying the effects of adolescent nicotine exposure on anxiety and mood disorders.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Laviolette (2021)
Variations in coil temperature/power and e‐liquid constituents change size and lung deposition of particles emitted by an electronic cigarette
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Lechasseur (2019)
Nicotine Dependence of Electronic Cigarette, Dual Combustible and Electronic Cigarette Users.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Lee (2021)
Further investigation of gateway effects using the PaTh study.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Lee (2020)
association of depression and suicidality with electronic and conventional cigarette use in South Korean adolescents.
Individual Clinical
Safety
Adverse Effects
Lee (2019)